~~<i id='E4312A79FB'><strike id='E4312A79FB'><tt id='E4312A79FB'><pre id='E4312A79FB'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：Wikipedia 2025-09-27 09:09:54 Page View：3398

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to bring more disabled researchers into academia
Next article： Peter Hotez and the public health issue of online harassment

explore

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

Bernie brings in new pharma CEOs to talk drug prices

Sen.BernieSanders(I-Vt.)Moneymaker/GettyImagesYou’rereadingthewebeditionofD.C.Diagnosis,STAT’stwice-

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

DarronCummings/APWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechne